The four main types of breast cancer are classified by which receptors the tumor cells carry: HR+/HER2- (hormone receptor positive), HR+/HER2+ (both hormone receptor and HER2 positive), HR-/HER2+ (HER2 positive only), and HR-/HER2- (triple-negative). These subtypes are listed in order of prevalence, with HR+/HER2- being the most common. Each type behaves differently, responds to different treatments, and carries a different outlook.
These four subtypes are determined by testing a tissue sample from the tumor for two things: whether the cancer cells have receptors for the hormones estrogen or progesterone (hormone receptor positive), and whether they produce high levels of a growth-promoting protein called HER2. The combination of those results places the cancer into one of the four categories and shapes nearly every treatment decision that follows.
How Subtypes Are Determined
After a biopsy or surgery, pathologists run a lab test called immunohistochemistry (IHC) on the tissue sample. This test checks for hormone receptors and HER2 protein on the surface of the cancer cells. IHC is fast, relatively inexpensive, and accurately characterizes HER2 status in about 95% of cases. When IHC results for HER2 come back borderline, a second test called FISH (fluorescence in situ hybridization) is used to look directly at the HER2 gene and confirm whether it’s amplified. Only about 36% of borderline IHC cases turn out to be truly HER2 positive on FISH testing.
These results matter because they tell oncologists exactly what’s fueling the cancer’s growth, which determines which therapies will work. A cancer that runs on estrogen, for example, can be starved of that hormone. A cancer driven by HER2 can be targeted with drugs that block that specific protein.
How This Differs From “Where It Started”
You may also hear breast cancers described by where they begin in the breast tissue. About 8 in 10 invasive breast cancers are invasive ductal carcinoma, meaning they started in the cells lining a milk duct. Roughly 1 in 10 are invasive lobular carcinoma, starting in the glands that produce milk. These describe the cancer’s location and cell structure, but they don’t tell you which receptors it carries. Any ductal or lobular cancer can fall into any of the four molecular subtypes. The receptor-based classification is what drives treatment planning.
HR+/HER2-: The Most Common Subtype
HR+/HER2- cancers are the most frequently diagnosed subtype. These tumors have receptors for estrogen, progesterone, or both, but do not overexpress the HER2 protein. Because these cancers depend on hormones to grow, hormone-blocking therapies are the primary treatment approach.
Within this category, doctors further distinguish between what researchers call Luminal A and Luminal B patterns. The difference comes down to how fast the cancer cells are dividing, measured by a protein called Ki-67. Luminal A tumors have low Ki-67 (under 14% of cells actively dividing), tend to be lower grade, and generally grow slowly. Luminal B tumors have high Ki-67 (14% or above), grow more aggressively, and are more likely to need chemotherapy in addition to hormone therapy. This distinction carries real weight: studies show that Ki-67 levels and progesterone receptor status can separate HR+/HER2- cancers into groups with significantly different long-term outcomes.
HR+/HER2+: Dual-Positive Cancers
These cancers carry hormone receptors and also overexpress HER2. Having both drivers gives oncologists two angles of attack: hormone-blocking therapy to cut off the estrogen supply, and HER2-targeted therapy to shut down the growth signals from that protein. The Ki-67 proliferation rate in these tumors varies, so their aggressiveness is less predictable than in the purely hormone-driven subtypes.
Because HER2-positive tumors are essentially addicted to the HER2 protein for survival, blocking it can be remarkably effective. Research has shown that when HER2 activity is suppressed, tumors that depend on it can shrink or regress. This biological vulnerability is what makes HER2-targeted treatments one of the major success stories in breast cancer care over the past two decades.
HR-/HER2+: HER2-Enriched Cancers
HR-/HER2+ cancers lack hormone receptors entirely but produce extremely high levels of the HER2 protein. In these tumors, the HER2 gene can be expressed at 25 to 50 times its normal level, and the protein itself can be increased 40 to 100 times over. This massive overproduction hijacks the cell’s normal growth controls, driving rapid and unregulated division.
Without hormone receptors, these cancers don’t respond to hormone-blocking drugs. Treatment relies on therapies that specifically target the HER2 protein. Before HER2-targeted treatments existed, this subtype carried a poor prognosis. The development of drugs that exploit HER2 dependence transformed outcomes for many patients, since these tumors often can’t survive without their amplified HER2 signaling.
HR-/HER2-: Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) tests negative for estrogen receptors, progesterone receptors, and HER2. With none of these targets available, the treatments that work for the other three subtypes don’t apply here. This makes triple-negative cancers harder to treat and, on average, more aggressive.
TNBC tumors are about 10 times more likely to be high grade than other breast cancers, meaning the cells look very abnormal under a microscope and tend to divide quickly. People with TNBC are often diagnosed at a younger age and at a more advanced stage compared to those with other subtypes.
There’s a notable genetic connection. Among women carrying a BRCA1 gene mutation, 48% develop triple-negative breast cancer, compared to just 12% of women without that mutation. Among women under 40 diagnosed with TNBC, about 8% carry a BRCA1 mutation even without any family history of breast or ovarian cancer. This link is strong enough that a TNBC diagnosis, especially at a young age, often prompts genetic testing.
Despite being grouped as a single subtype, triple-negative breast cancer is actually an umbrella category that includes several biologically distinct subtypes. Some are driven by immune system interactions, others by features of the surrounding tissue environment. This diversity is one reason treatment response varies widely within the triple-negative group, and it’s also why newer treatment strategies, including immunotherapy, have gained ground for certain triple-negative cancers.
Why Subtype Matters More Than Stage Alone
Stage tells you how far a cancer has spread. Subtype tells you how it behaves and what will stop it. Two people with the same stage of breast cancer can have very different experiences depending on their subtype. A stage II Luminal A cancer, for instance, may respond well to hormone therapy alone and carry an excellent long-term outlook. A stage II triple-negative cancer of the same size typically requires a more intensive treatment approach and closer monitoring.
Knowing your subtype also helps predict how the cancer will respond over time. Hormone receptor positive cancers can sometimes recur years or even a decade after the original diagnosis, while triple-negative cancers that do recur tend to do so within the first few years. HER2-positive cancers, once among the most feared subtypes, now have much better outcomes thanks to targeted therapies that exploit the tumor’s dependence on HER2 signaling. Each subtype carries its own timeline, its own vulnerabilities, and its own treatment playbook.